CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 71 enrolled
Drug / intervention
bimatoprost ophthalmic solution 0.03% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01023841
NCT01023841Phase 4Completed
CompareCT.gov

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Allergan·interventional·Posted Dec 2, 2009·Updated Apr 17, 2019

In Brief

A Phase 4 clinical trial evaluating bimatoprost ophthalmic solution 0.03% and Vehicle Sterile Solution for Eyelash Hypotrichosis and Alopecia Areata. Completed, enrolled 71 participants across 2 sites in 2 countries.

Detailed Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough eyelashes) in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyelash Hypotrichosis, Alopecia Areata
CountriesBrazil, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2009
Enrollment StartJun 1, 2010
Primary CompletionNov 2, 2012
Study CompletionNov 30, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.6 years ago

Interventions

bimatoprost ophthalmic solution 0.03%drug

One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

Vehicle Sterile Solutiondrug

One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.